210 PET Imaging Among First to Offer PSMA-Targeted PET Imaging for Men with Prostate Cancer
September 21, 2021
Men with prostate cancer are now able to receive targeted positron emission tomography (PET) imaging with PYLARIFY, a new prostate-specific membrane antigen (PSMA) imaging agent. 210 PET Imaging, a PET/CT scan facility in Cary, NC, is the first in the Carolinas to use the Food and Drug Administration-approved imaging agent to identify suspected metastasis or recurrence of prostate cancer. PYLARIFY (piflufolastat F 18) was developed by Lantheus and is the first and only commercially available approved PSMA PET imaging agent for prostate cancer.
Andrew G. Moran, MD, board-certified abdominal and molecular imaging radiologist (Nuclear Medicine and PET CT) with 210 PET Imaging and Head of Nuclear Medicine at Raleigh Radiology says, “As the first PET Imaging in the Carolinas to offer this new imaging agent, we hope to reach even more prostate cancer patients to provide them with this latest diagnostic tool. Being able to stage and restage prostate cancer effectively will help referring oncologists and urologists develop their patients’ care plans faster and more effectively.”
“We are so pleased to bring this imaging agent used in conjunction with our new PET/CT imaging technology to identify suspected or recurrence of prostate cancers,” said Tom Hughes, senior vice president and administrator for WakeMed Cary Hospital. “Using these latest diagnostic advancements, prostate cancer patients can receive a relatively quick and accurate scan in a convenient location close to home and closer to recovery. It is a timely addition to our services as September is Prostate Cancer Awareness month”
Prostate cancer is the second most common form of cancer affecting men in the United States -- an estimated one in eight men will be diagnosed with prostate cancer in their lifetimes.1 Of men with localized prostate cancer who undergo initial curative intent/management, up to 50% may experience recurrence of their disease within ten years of treatment.2 Recurrent disease is often detected by a rise in PSA levels; however, conventional imaging, especially at low PSA levels, is not able to identify the location and extent of the disease in the majority of cases.3,4
PYLARIFY® (piflufolastat F 18) (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastasis to determine the presence or absence of recurrent and/or metastatic prostate cancer.
Pylarify is the latest in advanced imaging agents available, and 210 PET Imaging at 210 Ashville Avenue in Cary is the first location to offer the agent in the Carolinas. The 210 PET Imaging center features the Siemens Healthineers Biograph Vision, which is the latest, next-generation PET/CT scanner with advanced imaging technology, artificial intelligence (AI) capabilities and quicker scan times with a wide bore for enhanced patient comfort. The 210 PET Imaging center is part of a joint venture between WakeMed and Raleigh Radiology.
About Raleigh Radiology
Opened in 1950, Raleigh Radiology is Wake County’s oldest radiology practice. Offering advanced adult and pediatric diagnostic imaging across the Triangle, our subspecialized board-certified radiologists are dedicated individuals who see patients at our imaging centers as well as provide professional services for all WakeMed Health & Hospital facilities. With seven locations across the Triangle, Raleigh Radiology is an ACR-designated Breast Imaging Center of Excellence. At Raleigh Radiology, our goal is to provide the highest quality cost-effective imaging while offering compassionate care for our patients. To learn more about Raleigh Radiology, visit www.raleighrad.com.
About WakeMed Health & Hospitals
Serving the community since 1961, WakeMed is a not-for-profit health care system founded and based in Raleigh, N.C. WakeMed exists to improve the health and well-being of our community by providing outstanding and compassionate care to all. WakeMed’s 976-bed system comprises a network of facilities throughout the Triangle area, including three full-service hospitals, seven emergency departments, a dedicated Children’s Hospital and Rehabilitation Hospital, more than 80 physician offices and Wake County’s only Level I Trauma Center. WakeMed’s mission-driven team includes more than 10,000 employees, 1,500 volunteers and 1,300 affiliated physicians, along with the more than 580 physicians and providers with WakeMed Physician Practices – all representing the best minds and the biggest hearts and the finest quality in health care and community health. For more information, visit www.wakemed.org or follow WakeMed on Facebook, Twitter and Instagram.
About Prostate Cancer
Prostate cancer is the second most common form of cancer affecting men in the United States -- an estimated one in eight men will be diagnosed with prostate cancer in their lifetimes. The American Cancer Society estimates that in 2021, almost 250,000 new cases of prostate cancer will be diagnosed, and more than 30,000 men will die of the disease. Approximately 3.1 million men in the United States currently count themselves as prostate cancer survivors.1
###
1American Cancer Society. Facts & Figures 2021. American Cancer Society. Atlanta, GA. 2021.
2Mena et al. 18 F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy J Nucl Med 2020 Jun;61(6):881-889. doi: 10.2967/jnumed.119.234799. Epub 2019 Nov 1.
3Alipour et al. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Ther Adv Med Oncol. 2019; 11: 1758835919876828.
4Taneja Imaging in the Diagnosis and Management of Prostate Cancer Rev Urol. 2004 Summer; 6(3): 101–113.
Additional Information:
WakeMed Health & Hospitals
Kristin Kelly | Phone: 919-350-5921
Email: krkelly@wakemed.org